As of 1:30 PM on the 22nd, GemVax is trading at 26,000 KRW, the same price as the previous day. The trading volume is 1,842,531 shares, which is about 30.92% of the previous day's volume. GemVax is known as a manufacturer of contamination control equipment for the semiconductor and display sectors.
On September 21, researcher Oh Byung-yong from Hanyang Securities stated, "1) Full data from Phase 2 clinical trials and research results on the mechanism of action will soon be published through a paper, 2) Around October, a clinical trial plan and conditional marketing authorization application for domestic Phase 3 clinical trials are planned to be submitted. Additionally, 3) the expansion of the US clinical protocol is currently under discussion with the FDA, and the results of the consultation will be announced soon. Bio stocks attract market attention only when there are events. GemVax has now reached a point where events are concentrated. The stock price has not risen relatively much. It is a good time to buy." He set the target price for GemVax at 45,000 KRW.
Over the past five days, individual investors have net sold 59,123 shares of GemVax, while foreigners and institutions have net bought 2,566 shares and 126,283 shares, respectively.
※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
